Home » Topics » Endocrine/metabolic, BioWorld Science

Endocrine/metabolic, BioWorld Science
RSS

Cholesterol absorption inhibitors from Schering-Plough

July 19, 1996

Bile acid reabsorption inhibitors described by Glaxo Wellcome

July 19, 1996

Cathepsin L inhibitors described by Takeda

July 19, 1996

Vitamin D compounds with preferencial calcemic and cell differation inducing activity described

July 19, 1996

RWJ-26819: Non-steroidal progestin agonist from R.W. Johnson

July 12, 1996

U.K. and Canadian approval sought for Alora

July 12, 1996

New formulation of rhGH from Alkermes and Genentech

July 12, 1996

KGR-1380: A novel glycation inhibitor

July 12, 1996

Aldose reductase inhibitors described by Grelan

July 12, 1996

Optro enters U.S./Canadian phase II trials

July 12, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal
BioWorld
Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...